INTRODUCTION
The issue of pharmaceutical drug affordability has moved to the forefront of political and public health concerns over the past decade. The increasing prices of prescription drugs in the United States have denied a class of people access to medication. This problem is not limited to the United States; similar and often more acute dilemmas can be seen in many developing countries.
The high prices of pharmaceuticals in the United States can be attributed to several factors. The two most prevalent are the tempQrary monopolies large pharmaceutical companies gain upon receiving patents for their products, and the stringent standards which those drugs must meet under Food and Drug Administration (FDA) regulation.
• The monopoiies granted tO the patenting companies are not without justification because those companies must invest millions of dollars in research and development (R&D) of these new drugs. 2 The patent monopolies act to fulfill the companies' investment-backed [Vol. 2:267 expectations and create incentives for the companies to continue their costly research in pursuit of new and improved phannaceuticals. 3 The general rule of law is that patents do not extend extraterritorially; therefore, countries around the world have the capability to set up their own patent. requirements. 4 This creates divergent international standards, which breed, among other difficulties, many patent infringement issues. This is especially relevant to large pharmaceutical companies with global markets. 5 · In addition to the differing patent standards among countries, the intangible nature of patent rights makes them especially difficult to protect from infringement. 6 While large amounts of time and money must be devoted towards developing the initial chemical structure of a drug, once it has been detennined, it is much easier and less expensive to produce the actual drug product. 7 Anyone who did not invest their resources in the costly research and development process could easily replicate that chemical structure through inexpensive methods, such as reverse engineering, bypassing all of the necessary R&D costs. 8 In the United States, the high cost of pharmaceutical drugs has led to an increasing number of people turning to foreign phannaceutical manufacturers, commonly in Mexico and Canada, where cheaper, generic versions of the medication they need are available. 9 The manufacturers in these foreign companies are able to sell these drugs cheaper than the United States companies because they do not have the R&D overhead to recoup. 10 These drugs are also 3. Creech, supra note 2, at 600; see also Christopher Scott Harrison. Comment. Harrison 31, 2003 , at A14. The internet has greatly increased the American consumer's ability to reach foreign pharmaceutical manufacturers. While this note acknowledges that prescription and non-prescription drugs are imported into the United States from all over the world, the scope of this note will focus mainly on prescription drugs from Canada. In addition, any reference made to "foreign pharmaceuticals" or "foreign drugs" also includes American-made drugs sold in Canada by the authorized patent holder and subsequently re-imported into the United States, unless otherwise specified.
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10; See Bruce A Lehman, Intellectual Property Under the Clinton Administration, 21 GEO. WASH. J.INT'L L. & ECON. 395, 395 (1994) ("Other nations often look for a free ride, seeking to build their economies not by encouraging the innovation and creativity of their own people through strong protection for all forms of intellectual property, but by promoting intellectual property piracy through weak. laws or no protection at all.''). less regulated, 11 and some can be purchased without a prescription. 12 In addition to these safety issues, their use in the United States presents a question as to patent infringement
The escalating prices of pharmaceuticals in the United States have created an incentive for state governments to seek and even subsidize foreign pharmaceutical companies in order to provide lower priced pharmaceuticals to United States citizens who cannot afford the high prices in the United States. This creates several legal questions concerning whether a state, or even the federal government, could subsidize these foreign companies without violating existing United States law. This question consists of several issues, including whether this should be considered either a patent infringement under the United States Patent Code or a "taking'' under the Fifth Amendment of the United States Constitution. Moreover, if such governmental subsidies of foreign drug makers. are considered an infringement or a taking, the law is not clear as to how or by whom the patent-holding companies should be compensated. This is a novel issue and has not yet been ruled upon by the United States Supreme Court. This Note will focus on the different interests associated with the increasing problem of high cost pharmaceuticals and propose a resolution based on the notion of compromise.
Pharmaceutical pricing in the United States is a complex topic and one in which numerous parties have considerable interests involved. In addition, each of these groups influences the situation in their own individual way. Parts I, II, and III of this Note will assess the problem-who the affected parties are, the pharmaceutical industry's justification for their high prices, and the gravity of the situation that has evolved. Secondly, this Note will provide an overview of the evolution of Canadian patent law and the importation of Canadian drugs into the United States. PartV then evaluates the United States law applicable to the pharmaceutical drug importation issue. The conclusion outlines the proposals for action at the federal level, which entail a comprehensive structuring of a new. system aimed 8olely at the prescription drug industry. 
I. PARTIES AFFECTED BY THE INCREASED PRICES OF PHARMACEUTICAL DRUGS
A. The Elderly, Impoverished, and Uninsured [Vol. 2:267 While American pharmaceutical consumers in general pay more for prescription drugs than citizens in other developed countries, 13 the United Sui.tes' elderly and uninsured bear the heaviest burdens. The·problem of affordability has become exceptionally severe for older people who are unable to manage their finances when they become ill. 14 While prescription drugs represent a relatively small part of total consumer household spending on average, 15 this amount increases significantly with age. 16 Several factors are responsible for this trend, for instance, that the elderly are living longer 17 and sixty-five to seventy-five year old demographic has a low median income. 18 The poor are an additional class faced with the predicament of pharmaceutical drug affordability. In 1999, approximately 42.6 million people in the United States had no health insurance coverage whatsoever. 19 Without health insurance coverage, consumers are forced to pay for prescription drugs out-of-pocket, a next to impossible feat for many. 20 This survey focused on noncompliance due to high co-payments; however, the overall finding of noncompliance with prescription medication due to high prices can be applied to the uninsured as well.
choice of following a prescribed drug regime versus employing money for other needs, survey results indicate that noncompliance with th~ prescribed medication is common. A similar inclination is seen in the elderly. 22 Serious health.consequences often result when chronic diseases, prevalent in the aged population, are not treated according to the prescribed dosage. 23 
B. United States Federal Health Care Programs
Providing an avenue through which health care can be made available to all Americans has been a policy concern for several decades. The United States government established two national health insurance programs in 1965 in order to assist elderly and impoverished Americans to gain access to health care. 24 Medicare covers the elderly, persons with certain qualifying disabilitie~. and people with End-Stage Renal Disease, 25 while Medicaid acts to make health care available to the poor, 26 a class defined differently :from state to state. due to the states • ability to adopt independent need-based standards. 27 When these federal insurance programs were instituted, they did not cover outpatient prescription drugs as part of the mandated benefits package. 28 This has become increasingly problematic, especially among the aged population, as modem health care is relying more and more heavily on drug therapy. 29 The increasing price of phannaceutical drugs has only further exacerbated the situation. In response to the bilateral problems of controlling drug prices and providing adequate coverage, Congress recently reformed Medicare's prescription drug policy to provide prescription drug benefits to some Medicare recipients. 30 · Under this plan, which is scheduled to be fully implemented by January of2006, low-income Medicare beneficiaries, including those who also receive Medicaid coverage in addition to Medicare, would receive additional coverage of their self-administered prescription drug costs. 31 Critics of the reform state it does not provide the types of benefits seniors need and comes with a large price tag in a time of an already significant government deficit 32 While this program will assist the elderly in paying the high prices of prescription drugs, it does not provide similar benefits for the poor. "Although some prescription drug benefits are available through Medicaid, the federal mandate does not require such coverage .
• m Despite the growing amounts of both state and federal funds provided to the Medicaid program and the millions of citizens who have received aid, significant numbers of the populace are excluded from coverage. 34 Because of the differences among state eligibility requirements, a significant number of individuals who fall below the federal poverty level do not receive aid from Medicaid, and are unable to meet their prescription drug needs. 35 Even if an individual is eligible for the Medicaid program, there are significant disparities in payments among states. 36 Thus, a Medicaid recipient's status may depend upon the state in which he or she resides.
However, amidst this environment of rising costs, state governments are not necessarily acting unreasonably by enforcing limited Medicaid eligibility requirements and restricted optional coverage plans. 37 States do not operate with unlimited funds and society is not often receptive to large tax increases. One possible solution to the disparate coverage problem may be to remove prescription drug benefits entirely from Medicare and Medicaid and vest all prescription drug authority in one comprehensive federal program that eliminates the states' discretion in defining need. While such a system would not eliminate the need for tax funding, it would allow the cost of the program to be spread more evenly across the nation.
II. FACTORS CONTRIBUTING TO THE INCREASED COSTS OF PHARMACEUTICALS IN THE UNITED STATES
The United States drug industry operates using free market pricing, but American drug prices are the highest in the world 38 Several other factors contribute to the elevated costs of pharmaceuticals in the United States besides the strength attributed to patent holders' rights. An . escalation in the number of prescriptions, including unwarranted or improper drugs, which add to demand, is one such alternative source. 44 Likewise, a general increase in drug prescriptions is contributing to the increase in the costs of such drugs. 45 In addition, in the modern medical community there has been an increasing trend towards alternative means of treatment; namely, the substitution of prescription drugs in the place of medical procedures. 46 Additionally; the United States requires all new drugs to obtain FDA approval prior to their placement in the market. The FDA's Center for Drug Evaluation and Research (CDER) was created to assure that all prescription and over-the-counter drugs are safe and effective; essentially, that the drug's benefits to society outweigh its potential risks. 47 After the CDER determines a new drug is safe for consumer use, it continues to serve as a "consumer watchdog for the more than 10,000 drugs on the market to be sure they continue to meet the highest standards.'>48 Because the United States pharmaceutical companies must also satisfy the prerequisite of FDA approval to bring their new drugs to market, their expenses are increased all the more.
Another key contributing factor to the high price of pharmaceutical drugs in the United States is direct-to-consumer (DTC) advertising. Over the past decade, pharmaceutical companies have steadily increased their budgets for marketing, advertising and public relations. 49 Accompanying the additional marketing expenses that pharmaceutical companies must account for in their drug pricing, DTC advertising has improved consumer awareness and placed . pressure on physicians to prescribe the medications consumers request. so Advertising increases the costs consumers must cover when paying for their drugs and promotes the shift of the medical field from a service to a business. Such a shift naturally promotes the pharmaceutical company's attempt to maximize profits, therefore increasing product prices in accordance with increased demand.
In addition, consumer demand is relatively inelastic in relation to the price of prescription drugs because such drugs are often necessary to the person's ability to function. 5 1 Often very few realistic drug substitutes exist and in certain cases, once prescription drug use has begun, it must be continued for a continuous period of time (e.g., anti-depressants). Moreover, numerous prescription drugs can be highly addictive, which can affect such a drug's demand as well. Where consumer demand is inelastic to price, phannaceutical companies can charge more for a product than they could in a· market where consumer demand fluctuates in response to drug price. 5 2 With such a strong and stable consumer demand in addition to the limited governmental regulation in this area, pharmaceutical companies ultimately set the price of prescription drugs in the United States. 5 3
A. General Pricing Structure of Pharmaceutical Drugs in the United States
As mentioned above, pharmaceutical manufacturers operate in a free market system and are able to price products in the United States at whatever level they wish, subject to minimal structural restrictions. 54 Most of these firms are engaged in all phases necessary to bring a prescription drug to market, including the "[R&D] of different compounds, pushing new medicines through clinical trials, obtaining FDA approval, and the advertising and marketing of new drugs. " 55 Because these pharmaceutical manufacturers are involved in every aspect of bringing a drug to market, they have broad discretion in setting prices. 56 R&D expenses are the chief component behind the high costs of pharmaceutical drugs. To bring a new drug to market requires a substantial investment of time and resources. In addition, many of the costs associated with this process are sunk costs and therefore, largely unrecoverable once spent. 57 Studies indicate that the average new drug costs $800 million to develop and bring to market, 58 a process which takes an average of fourteen years. 59 While this high cost seems unreasonable at first glance, it is necessary to consider that "of every 5000 potential new drugs tested in animals, only five are 51. PATRICIAM promising enough to be tested in humans. Only one of those five is eventually approved for marketing.'>60 Logically, the revenues derived from successful medicines must not only cover the R&D expenses involved in their own development; but also the R&D costs of the unsuccessful medicines as well. 61 Moreover, a pharmaceutical company must have the financial resources in place to develop and test thousands of compounds, knowing that very few of them will ever reach consumers and thereby potentially reap a profit 62 Thus, the profits from the successful drugs must be high enough to cover the R&D expenses of the drugs that never reach the market. 63 If drug manufacturers charged only the marginal cost of drug production-the cost of making each new pill-they would never recover their research costs, and the drug business would not be profitable. 64 While critics concede developing and introducing a new drug into the market is an unquestionably expensive process, they have pointed out''that the billions of dollars spent on R&D do not come out of the drug companies' pockets alone.'>6s In 1994, the United States federal government contributed fifty-five percent ofthe total amount spent on pharmaceutical drug R&D. 66 The National Institutes ofHealth (NIH) is the main source of most federally provided health care R&D funds. 67 NIH funds have been used to develop one third of the most important drugs developed between 1965 and 1992. 68 While federal funding does exist, pharmaceutical companies invest tremendous amounts of their own money on R&D as well. It is not uncommon for large pharmaceutical companies to invest several billion dollars annually in R&D, over and above any federal aid they may receive.~ If pharmaceutical 60. The Ballooning Price Tag, supra note 58; see also QUESTIONS ABouT MEDICINES, supra note 2, at 2 (providing graphical depictions of the R&D costs and stating, "[t]he average cost ofbringing one new medicine into the market is $500 million ... [and] takes an average of twelve to fifteen years to discover and develop.;. Note the $500 million cost to bring to market was the statistic as of June of2000, which subsequently increased to $800 million by December of2001. Abbot Laboratories estimates it costs $900 million to carry one drug all of the way through to market. JOHN LEONARD, ABBoTr LABoRATORIES R&D relied solely on subsidies from the federal government, the level of innovation currently seen in the United States pharmaceutical industry would be reduced, simply because the government could not afford to fund the current level ofR&D expenses. However, as long as individual companies are spending their own money on R&D, they will be at liberty to set their prices (absent government price caps or other limitations).
B. Effects of Increased Pharmaceutical Prices in the United States
Two main effects have resulted from the increased costs of United States phannaceuticals. The high profits in the American drug industry create strong incentives for United States pharmaceutical companies to promote research of new drugs. Thus, high prices ensure that Americans will continue to promote the development of, and have access to, the most innovative drugs in the world. 70 Increased United States innovation is made apparent by the substantially longer wait international consumers must endure for access to new medicines as compared to American consumers. 71 On the other hand, cutting edge medicines are of no use to consumers who cannot afford to purchase them. 72 An increasing number of people in today's society are finding themselves unable to afford their prescriptions and are consequently being forced to seek similar pharmaceuticals from more affordable sources outside of the United States. 73 While this problem is not limited to the elderly, the increase in the number of elderly people in the United States has added to the gravity of this problem. "Everyday millions of Americans ... must choose between buying food or medication or between [sic] taking the fully prescribed dosage of medicine [,] forced to choose between poor quality of life and the risk of possibly using counterfeit, contaminated, or ineffective foreign pharmaceuticals, these consumers are deciding to take their chances. A balance must be struck between the consequences of increased prices of United States pharmaceuticals and the promotion of prescription drug innovation. While the United States asserts that it produces the world's leading drugs, there is no assurance that the people who need these drugs will be able to afford them. 75 Advocates of the current pharmaceutical system could argue that the Supreme Court has held there is no constitutional right to health care, 76 and therefore, there is no legal basis for prescription drug policy reform. On the other hand, it could be contended that a moral obligation exists to assist the disadvantaged. 77 If viewed from a purely business perspective, United States pharmaceutical companies are merely creating a product and selling that product for a profit. Such companies are provided protection for their patent rights under the United States Constitution. 78 
ill. FOREIGN PHARMACEUTICALS AND QUALITY ISSUES
Because of the pricing discrepancy between United States and foreign pharmaceuticals, many Americans have turned to importing foreign manufactured drugs.on their own. 80 The potential savings are hardly trivial, given that an estimated "$90.7 million a year could be saved if drugs for state employees and retired employees were bought across the border in Canada.
•.St While American consumers claim this is the only way they can obtain the medicines they need, the safety of such a practice is questionable. Above aU, foreign pharmaceuticals are not subject to regulation by the FDA, leaving much to chance in terms of the drugs' safety. 82 One example of the risks posed by consumer importation of foreign drugs is provided by a 2001 Congressional study. The report found that the large amounts of drugs that had been re-imported into the United States have created health and safety risks to American consumers. 83 The analysis focused primarily on American drugs that have been re-imported into the United States as American goods returned (AGRs). A major problem presented by reimported drugs lies with the improper handling and shipping by foreign countries, which introduces the possibility that the drugs may have become subpotent or adulterated. 84 The Congressional report also revealed that reimportation of American drugs acted as a catalyst and cover for the foreign counterfeit drug market 85 When a pharmaceutical manufacturer is granted a patent for its new drug, the chemical structure of that patented drug, and frequently its chemical synthesis, can be found in either the patent application or in subsequent pharmaceutical literature. 86 substances, into the United States from Mexico, Canada, and elsewhere." 87 With advancing technologies, the Internet providing easy access to information, and the ability to set up web ventures, counterfeiting pharmaceuticals has become an increasingly more prevalent and serious problem. 88 Frequently, such counterfeiters do not even need access to the drug's chemical structure. 89 Canadian drugs are not FDA regulated, providing no guarantee for their safety or efficacy. 90 Therefore, when Americans travel to Canada to purchase cheaper pharmaceutical drugs they cannot be sure what they are buying. In addition, it is possible that· such consumers could be unknowingly buying counterfeit medicines which could cause substantial hann to their health and livelihood. Thus, it is necessary for the United States to adopt a solution which caters to keeping drugs both affordable and safe.
IV. CANADIAN. PATENT LAW
Only forty years ago, the high costs of pharmaceutical drugs were causing problems in Canada similar to the dilemma facing the United States today. 91 Canada was unable to promote the public welfare due to the extensive prices of pharmaceutical drugs. At that time, the prices of Canadian pharmaceutical drugs ranked among the highest in the world. 92 In 1968, the Canadian government responded by enacting legislation that mandated the licensing of the patented drugs to generic manufacturers in order to have the effect of price control. 93 Nevertheless, twenty years following the 1968licensingmandate, Parliament decided an unreserved compulsory system excessively encroached upon patent holders' rights, effectively diminishing incentive for innovation among researchers. 94 While the compulsory licensing system was effective in decreasing the costs of phannaceutical drugs to the public, it also decreased the monetary incentive for Canadian pharmaceutical manufacturers to invest in ongoing research in pursuit of novel drugs and, therefOre, new patents.
Moreover, the United States was exerting pressure on Canada to reject the compulsory licensing system because it enabled individuals or corporations 87 to obtain a compulsory license from the Canadian Commissioner of Patents and use a United States patented process to manufacture a drug in Canada. 95 In effect, the compulsory licensing system was facilitating the misappropriation of United States patents. The United States opposition to the Canadian licensing policy was so powerful and widespread that by October of 1985, the United States Trade Representative complained in his annual report ''that Canada's compulsory licensing policy was costing U.S. companies 'hundreds of millions of dollars .... 96 Pharmaceutical companies in the United States were among the loudest voices heard in favor of using the United States' political force to encourage Canada to abandon its compulsory licensing system.
Influenced by interior concerns as well as political pressure from the United States, the Canadian Parliament implemented a compromise by granting the patent holder an exclusive term for at least seven years, after which mandatory licensing could be imposed. <n However, such a compromise was not sufficient to satisfy the United States, and after extensive negotiation, the North American Free Trade Agreement (NAFTA) eliminated compulsory licensing altogether. 98 In 1993, Canada implemented Bill C-91 and brought Canada into compliance with NAFTA's terms. 99 Seven years prior to Bill C-91, the Canadian Parliament had established the Patented Medicine Prices Review Board (PMPRB) in anticipation of NAFTA's adoption. 100 The PMPRB remains in effect today and serves as a review board possessing the power to compel disclosure of Canadian pharmaceutical manufacturers' confidential information concerning their drug pricing. 101 After the PMPRB reviews the pricing information, it sets a wholesale price for the drug, which incorporates and accounts for a reasonable return on the patent holder's investment. 102 Initially the PMPRB was authorized to invalidate the drug's patent in Canada if the manufacturer failed to comply with the mandated information requests or pricing. 104 However, in 1993, that invalidation power was stripped from the board and replaced by the power to merely impose financial penalties.105· Canada continues to use the PMPRB as the price control authority over pharmilceutical drugs, and it has been successful in keeping drug prices low. 106 The evolution of Canadian patent law offers a valuable tool to the United States.· in drafting prescription drug reform. History illustrates the direct correlation between strong patent rights and increased innovation and vice versa. Likewise, the creation and success of the PMPRB shows that a review board can exist and determine reasonable market prices for pharmaceutical drugs.· While following Canada's lead entirely may not be the most effective approach, 107 it would be wise to consider Canada's experience·in reshaping United States policy. '
V. UNITEDSTATESPATENTLAWS
A. Constitutional Grant of Power
The power to patent an invention originates directly from the United States Constitution: "The Congress shall have power . . . to promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries •••• " 108 This reference to patent protection in the founding document of the United States evidences the long term commitment and historical importance attributed to patent rights. The main pwpose of the patent system in the United States is exactly as the patent clause reads, to promote the progress and science of the useful arts. While inventors are rewarded via the monopoly bestowed upon them when they are granted a patent, the monopoly is merely a means to that end. 109 The patent clause grants all governing authority to Congress, A textual reading of this clause suggests Congress has a type of all or nothing ability to grant patent rights: "Congress may either grant exclusive rights in the patented article, or grant no rights at all."Ho Patent laws allow the patent holder to. exclude people from using, providing or selling the invention throughout the United States in the absence of a license granted by the patent holder. 111 In fact, the United States Supreme Court has construed the patent clause narrowly, indicating that ''the language of complete monopoly has been employed." 112 In the case ofpha.rmaceutical drugs, patent rights bar competition from generic competitors for a period of twenty years from the filing of ~e patent. 113 Pharmaceutical companies consider this term vital to their survival and to the continuous production of innovative drugs in order to combat the "free rider problem." 114 Moreover, because only one out of every ten drugs produced by pharmaceutical companies actually makes it to the market, the monopoly granted through their patent rights affords them the funds necessary to recoup their R&D expenses of not only the drug that is being sold, but the other nine drugs which did not advance into the marketplace. 115 
B. International Influence on United States Patent Law
Extraterritorial Effects ofUnited States Patents
While the Constitution and subsequent legislation confer the benefits of a monopoly upon the patent holder, these rights generally only have effect within the borders of the United States. Courts and analysts have often stated that patent rights do not have any effect abroad, absent some form of infringement within the United States. 116 118 However, it is clearly a violation of patent rights when American citizens obtain such "generic" medicine from Canada and transport these drugs into the United States for their use. 119
The Doctrine of Exhaustion
· · Nevertheless, a fundamental limitation on patent rights is the doctrine of exhaustion upon first sale. 120 The doctrine of exhaustion has not been codified by the United States' Patent Act, however, it has been clearly established in common law . 121 The courts have justified this doctrine by stressing that the patent purpose 122 is accomplished once the patent holder has received the benefit of the initial sale of the patented article. 123 While Canadian drug manufacturers are selling generic versions of the United States patented drugs for discounted prices, American-made drugs are also available in Canada. Currently, it is not uncommon for individuals or companies to purchase American-made pharmaceuticals in Canada, where the drugs are cheaper, and subsequently re-import those drugs to be resold in the United States. 124 These "re-imported" drugs are classified as parallel imports, which are goods sold or authorized for sale abroad by the United States patent holder, then subsequently re-imported and sold in the United States without the original patent holder's authorization. 125 Once re-imported into the United States, the goods are in direct competition with the patent holder's goods. For that reason, international application of the doctrine of exhaustion is inherently capable of frustrating patent holders' attempts to maximize the value of their property rights. 126 Two competing theories have emerged regarding the doctrine of exhaustion: the "international exhaustion" theory, providing the doctrine of exhaustion should apply regardless of the location where the goods are sold, and the "domestic exhaustion theory," providing the doctrine of exhaustion should be limited to patented articles manufactured and initially sold within the territory of the United States. 127 International exhaustion is a controversial theory because it is contrary to the traditional notion that patent rights do not extend extraterritorially. 128 Patent owners, especially in the pharmaceutical industry, argue that because patent rights are created by "domestic statutes of restricted territorial scope," the discounted sales of their patented products in a foreign market cannot exhaust their domestic patent rights. 129 Moreover, the United States patent holders assert that because they are selling their drugs at a discount to foreign consumers, they have not received full value of their patented product. 13o The United States has not yet recognized the notion of international exhaustion with respect to patented items, although it has tolerated the theory in certain categories of copyrighted and trademarked goods. 131 Moreover, the United States Patent Act expressly provides that the unauthorized importation of a patented invention is an actionable infringement. 132 Finally, the United States Supreme Court enjoined the importation of a product covered by a United States patent but acquired abroad from an authorized source in its only decision regarding parallel imports of patented goods. 133 Because the doctrine of exhaustion has been limited to domestic application, a state or the federal government would be liable for infringement if they attempted to subsidize the re-importation of United States pharmaceuticalS bought in Canada.
C. The Fifth Amendment and Just Compensation
A patent is a property right conveyed upon the patent holder as a reward for their innovation. 134 Thus, its use is subject to all protections and limits afforded by the Fifth Amendment to the United States Constitution. The Fifth Amendment imparts, "[n]o per8on shall ... be deprived of life, liberty, or property, without due process of law; nor shall private property be taken for public use, without just compensation. " 135 In the proverbial bundle of rights which symbolize the rights characteristic of property, perhaps the most important stick is the power to exclude others. 136 From a patent perspective, this is an essential right, as the substantial value of a patent is derived from the patent holder's ability to exclude potential competitors from manufacturing the patented product, resulting in. the patent holder's domination of a niche in the industry. A patent holder can bring an action directly against the alleged infringer if that infringer is a member of the private sector, however, when the infringement is one of government action, the law is more complicated.
Federal law waives the United States govemritent's immunity from private suit, while concurrently allowing the federal government or its contractors to legally infringe upon a valid patent for the government's use. 137 Where the government infringes upon a patent on section 1498 grounds, this is a taking under eminent domain, 138 which entitles such a patent holder to Whenever an invention described in and covered by a patent of the United States is used or mailufilctured by or for the United States without license of the owner thereof or lawful right to use or manufacture the same, the owner's remedy shall be by action against the United States in the United States Court of Federal Claims for the recovery ofbis reasonable and entire compensation for such use and manufacture .... patent taking under eminent domain can be likened to the government offering fair market value for a residence in the projected path of a new highway system. While the government is authorized to take the house, compensation must be made to the owners at a fair and just price. Likewise, jllst ·as a homeowner is prohibited from refusing to sell their residence, section 1498 preeludes a patent holder from asserting an injunction against the United States to prohibit use of his patent. 140 However, this statute does not eliminate the patent holder's Fifth Amendment right to just and reasonable compensation. " [l] f taking the property is truly important for the good of the state, the state (and the taxpayers who support it) should be willing to pay a fair and just price for it. " 141 Determining that fair and just price introduces another complication into the Fifth Amendment scheme. When pharmaceutical companies price their ckugs they take into account that the profits from the successful drug must ()()V.er the R&D costs of the other drugs that did not reach the market. 142 The exact R&D costs of the unsuccessful drugs could also be a question of accounting and the length of time that the pharmaceutical companies choose to sprea9 their loss. Future profits and loss spreading make it difficult to determine exactly what fair and just compensation would be in any given situation.
D. Compulsory Licensing as a Taking
Jn the patent context, a taking by the United States government has traditionally been in the form of a "compulsory compensable license in the patent." 143 Just compensation has usually been calculated as "reasonable royalty" for the use of that license, or when that cannot be established-as often is the case-another method of calculating the value of the appropriated patent will be employed. 144 States experienced a major threat to its national security as a result of bioterrorism. The designed release and distribution of Bacillus anthracis ("anthrax'') throughout the country created a widespread panic among the American public. Government discussion quickly moved section 1498 actions are employed by the government and a compulsory license is issued, the entire process could cost the government more, as the patent holding company must be compensated, and payment would be rendered to the generic pharmaceutical manufacturer that actually made the drug.l46
Pharmaceutical companies often strongly protest compulsory licensing, even when they are awarded what the courts determine to be reasonable and full compensation. One reason for this is that "reasonable compensation" is largely ambiguous on its face and the reasonableness of a damage award is likely to depend on whether the pharmaceutical companies or the courts are making the judgment. 147 Additionally, "a rule creating a disadvantaged compensation scheme for government appropriated patents would be perceived as weakening the intellectual property right for affected arts." 148 It would be reasonable to expect to see a reduction in investment in research areas more apt to be subject to governmental takings if such a government action became exceedingly widespread. 149 Companies would simply not be willing to invest the necessary capital on innovative research if the capability to make future profits was likely to be stripped, only to be replaced by ''reasonable compensation" to be decided by a court.
While the reasons pharmaceutical companies may be opposed to compulsory licensing are somewhat obvious, the United States government also has an interest in refraining from the appropriation of its patents. First, the United States has a strong interest in encouraging innovative research in the area of pharmaceutical drugs. It is perceivable that Canada's model of price regulation through compulsory licensing does not provide the incentive necessary to maintain the level of pharmaceutical innovation currently seen in· the United States. 150 Adequate incentives must be present in order for the United . States to remain among the countries with the highest levels of pharmaceutical innovation in the world. Therefore, investment in research and development of new drugs is vital.
A second incentive, and perhaps a less obvious one, is that the government may be hesitant to employ compulsory licensing because of its possible effect on international relations. The United States does not want to underto the compulsory licensing of the patent rights to ciprofloxacin, the only antibiotic approved by the FDA for treatment of inhalation anthrax, in order to decrease the cost of the drug by allowing a generic form to be produced by companies other than the original patent holder (the German pharmaceutical company, Bayer, A.G.). /d. at 125-28. However, before the government "overrode" the ciprofloxacin patent. Bayer promised to increase its production of the drug three-fold along with considerably reducing the price it charged the U.S. government. 
VI. POTENTIAL SOLUTIONS
American consumers pay the highest prices in the world for pharmaceutical drugs. In exchange for this financial burden, Americans enjoy increased access to the most innovative drugs, assuming their budgets allow. Development of new and innovative drugs is dependent upon the strength of patent laws, or analogously, the promise of future profits. Observing the evolution of the Canadian patent system provides reinforcement for this theory .. After the Canadian government weakened their patent laws-thereby depressing the possibility of profits for the drug companies--Canadian pharmaceutical innovation decreased.
Consumers may tend to under-value the possible benefits of a not-yetdeveloped drug, since the unknown benefits would be pitted against the likelihood of high prices at the pharmacy. American consumers must decide if they are willing to sacrifice the potential for future developments of new life-saving drugs for smaller bills in the short-term. Furthermore, if a high level of innovation is determined to be the ultimate goal, action should be taken by the federal government to create a solution for the class of individuals currently wiable to pay for prescription drugs.
While permitting the importation of pharmaceutical drugs from Canada may seem to be the straightforward and logical solution to the United States' increasing prescription drugs prices, in the long run it could have a severe and negative impact on American public health and the United States pharmaceutical industry. Because such drugs are not FDA regulated, the quality and effectiveness of foreign drugs cannot be guaranteed. Moreover, allowing foreign pharmaceutical drugs into the United States market, especially through internet purchasing schemes, amplifies the opportunity for counterfeit drugs to reach American consumers. Although increasing FDA funding may enable that agency to regulate foreign pharmaceutical imports, supplying FDA officials with the financing required to detect and police these imports would likely compel either large tax increases or a significant increase in the United States deficit. For these reasons additional methods should be explored to increase the affordability of United States pharmaceuticals to the American public, and our borders should be closed to pharmaceutical drug imports.
A. Patent Infringement
As a matter of law, if a state or federal government were to import pharmaceutical drugs into the United States that were identical or substantially similar to those under a United States patent, the United States patent holder would have a valid claim of infringement and would entitle it to just and fair compensation. Under the domestic exhaustion principle adopted by the Supreme Court, even American-made drugs sold abroad and subsequently resold in the United States without the original patent holder's authorization would be considered an infringement. In either of these cases, United States companies holding pharmaceutical patents could obtain an injunction against the infringer.
Section 1498 allows the federal government to prevent the patent holder from asserting an injunction against the United States. However, reasonable and entire compensation must be made for the use of the patent. The determination of what is reasonable and entire compensation for a pharmaceutical drug is a problematic and controversial process. If the government were to compulsory license a patented drug, determining its fair value would entail projecting the amount of future profits necessary to cover the R&D of not only the successful drug, but also the sunk costs of the unsuccessful drugs that never were approved for the market. If the United States government were to make a practice out of compulsory licensing, this would not only weaken United States pharmaceutical patents, but it would also undermine the United States' international stance that other countries must respect United States patents. Either consequence would effectively decrease incentive for pharmaceutical companies to invest the sizeable amounts of money necessary for innovation. While non-FDA regulated pharmaceuticals may not be the answer, a solution must be found, as the rising prices of pharmaceutical drugs in America is leaving significant amount of the population without access to pharmaceutical drugs.
B. Alternative Solution: National Prescription Drug Aid Program
The establishment of a centralized federal agency with limited and exclusive regulatory power over prescription drug prices may be the answer. If this new federal program were employed, all prescription drug authority could be removed from Medicaid and Medicare, eliminating any discrepancies between programs and providing equal protection for all who meet the eligibility requirements. The key to such a program would be achieving the most efficient need-based eligibility standard. Such eligibility standards :should expand upon those currently utilized by the Medicaid and Medicare programs in order to encompass the largest percentage of the uninsured population. Achieving this standard has the potential to save the government money in the long term, as providing preventative care through prescription drugs is often less expensive than providing emergency treatment. 154 Further research is needed to determine the income level at which an individual is likely to purchase pharmaceutical drugs, so as to achieve the appropriate eligibility standard.
Regardless of the solution adopted to combat the affordability problem of United States pharmaceuticals, it is highly likely additional funding will be necessary. If this prescription drug pricing agency were adopted, because of the program's federal nature, taxes could be spread throughout the entire United States population thereby reducing the impact on the individual. Investing federal taxes into the proposed program would be considerably more efficient than funding the regulation of foreign phannaceutical imports which would create new problems and additional costs in long run. Additionally, because the existing Medicare and Medicaid programs currently receive funding for their limited prescription drug benefit programs, a proportionate amount of those subsidies could be shifted to the new prescription drug agency. Likewise, because the two existing programs' pharmaceutical drug benefits would effectively be excised and consolidated into one separate program, this would produce a more efficient system. Theoretically, these factors could decrease the amount of additional taxation necessary to support the new agency.
C. Agency Price Determination
The proposed federal program would operate in a similar fashion to the recent Medicare Prescription Drug Benefit Act. The new agency would purchase the drugs from United States phannaceutical companies at a discounted price. Such price would be set by a review board similar to the PMPRB utilized in Canada. 154 . Janet O'Kee:tfe, The Right to Health Care and Health Care Reform, in HEALTH CARE REFoRM:AHUMANRlGHTSAPPROACH35,40-41 (AudreyR.Chapman,ed., 1994). Currently, the poor and uninsured must be admitted for expensive institutionalized care when their health has deteriorated enough that they require emergency treatment. Id. . Generally the costs associated with such emergency treatment greatly exceed the costs of the forgone preventative treatment. Id. The discrepancy between these two costs is passed along to taxpayers by increased medical bills to all of society. Id. [Vol. 2:267 This pricing board's authority would be limited to the federal program and would not extend to mandating price caps for the regular market. In contrast to the Canadian PMPRB, this pricing review board would not automatically be authorized to compel disclosure of United States pharmaceutical manufacturers' confidential drug pricing information, given that it is unlikely United States pharmaceutical companies would cooperate with such a scheme. The review board's main function would be to assess the global market for the pricing of equivalent medicines and negotiate with the United States pharmaceutical companies to set a price falling somewhere in between the United States and global market prices. Only in the event that a United States pharmaceutical company refuses to negotiate or agree upon a reasonable 155 price may the review board be afforded the power to compel confidential pricing information from the uncooperative company. The agency price will then be set according to the review board's evaluation of the pricing information. All compelled pricing information should be kept strictly confidential.
The new agency would then purchase the pharmaceutical drugs directly from the manufacturers at the price agreed upon. Eligible participants of the program could then purchase these drugs from the agency at the average global market price. For example, if the review board found the average global price of a certain prescription drug was $3.00 per pill and the price for the similar pill in the United States was $10.00, the review board and the United States patent holder would negotiate and set an agency price at $7.00 per pill. The agency would then purchase these pills from the pharmaceutical company at $7.00 per pill and subsequently make the drugs available to eligible individuals at $3.00 per pill. In this way, the agency would have to consume only a percentage of the pharmaceutical drug costs, thereby lessening the tax burden Americans must bear.
This program would provide a means for elderly and impoverished Americans to have access to affordable and FDA regulated pharmaceutical drugs. There is no reason this program should directly impact the market prices of United States pharmaceuticals. Any drugs sold to the new agency would be above and beyond the companies' current sales, thereby extending the reach of pharmaceutical companies to a sector of the market previously unable to afford their product. Due to the marginal costs associated with increased pill production, it seems the patent holders themselves can take advantage of the "free rider problem" while still increasing their profit margin since increasing production is not financially inhibitory. Therefore, United States pharmaceutical companies could continue to cover their R&D costs and innovation would be spared. Moreover, because the companies are being com-155. The term ''reasonable" should be defined prior to the adoption of the agency. A suggestion for the reasonable standard would be to set the price as a set percentage above the global market price, however~ the precise definition can be negotiated for when the plan is enacted.
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THE DISPARITY IN AvAILABILITY OF PRESCRIPTION DRUGS 293 pensated for their products, this solution avoids any Fifth Amendment quandaries~ While the additional taxation necessary to fund the agency would indirectly increase the.burden of phannaceutical drug prices on more wealthy Americans, this trend is not uncommon iri the United States. While critics may attack this program as throwing the weight of the problem onto the backs of the aflluent, this argument ignores the underlying predicament entirely. The problems associated with the current system of pharmaceutical drug pricing in the United States are not going to disappear without the implementation of a solution that impacts the public as a whole. The establishment of this new agency offers a solution that both meets the needs of Americans who are presently unable to afford pharmaceutical drugs, and protects United States pharmaceutical innovation and the safety of the United States pharmaceutical drug supply.
D. Closing the Borders
Merely establishing a centralized agency to help combat the affordability problem ofUnited States pharmaceutical drugs will not resolve the issue alone. Making American pharmaceuticals affordable for indigent individuals will be a significant step towards decreasing American consumer incentive to seek drugs outside of the United States. However, that incentive will remain for the people who do not qualify for aid. Consumers cannot be relied upon to entirely discontinue. seeking out less expensive foreign drugs without the possibility of repercussions in place. The most efficient approach to securing the safety of the American drug supply. is to close the borders entirely to foreign drug imports. It would be unrealistic to expect an embargo on the importation of pharmaceuticals to prevent all foreign drugs :from entering the market. However, making the act of importation illegal may inadvertently increase the price of foreign pharmaceuticals, thereby lessening their appeal.
Additional funding will also be required to implement the stringent importation prohibition. However, it is not necessary that such funding be derived :from tax dollars.· The United States pharmaceutical companies have a substantial interest in closing the borders to foreign pharmaceuticals, as the competition weakens their market foothold. Therefore, it would be in the United States pharmaceutical companies' best interest to fund the FDA's implementation of a prescription drug import embargo.
If adequate funding was not made available merely by placing the security control in the hands of these large companies, several avenues could be explored to increase their motivation. For example, United States pharma-.
ceutical companies have large budgets reserved for DTC advertising. If such companies complained of the burden associated with their border responsibilities, the federal government could simply prohibit DTC advertising for pharmaceutical drugs and those funds could then be devoted to securing the borders. Securing the safety of the American pharmaceutical drug supply is more essential to promoting the public health than marketing prescription drugs to vulnerable consumers in search of the ''magic pill."
Vll. CONCLUSION Clearly. the pharmaceutical pricing situation cannot continue as it exists today. The importation of foreign pharmaceuticals violates federal law. infringes upon patent rights. weakens United States patent protection afforded by the Constitution. and creates an imminent threat to the public health. Because of the number of competing interests. the most effective solution is one of compromise. The creation of a central federal agency may not be the optimal. solution. however. it illustrates that an answer. can be found in a middle ground. The competing and intertwined interests complicate the overall issue. but also provide valuable bargaining power for compronme. If the optimal balance is struck. it will be possiPle to make prescription drugs more affordable to the elderly and the uninsured while protecting drug innovation and quality.
